![]() |
市場調查報告書
商品編碼
2025038
靜脈曲張治療市場規模、佔有率、趨勢和預測:按產品、手術、最終用戶和地區分類,2026-2034 年Varicose Vein Treatment Market Size, Share, Trends and Forecast by Product, Procedure, End User, and Region, 2026-2034 |
||||||
2025年全球靜脈曲張治療市場規模為4.795億美元。展望未來,IMARC Group預測,該市場將以4.34%的複合年成長率從2026年成長至2034年,到2034年達到7.108億美元。北美目前佔據市場主導地位,預計2025年市佔率將超過47.8%。推動市場成長的因素包括人口老化、微創手術技術的進步、公眾意識的提高和醫療保健支出的增加,以及領先企業致力於創新和策略合作以拓展治療方案和地理覆蓋範圍。
隨著新型、高效且微創的靜脈曲張治療方法的推出,市場正蓬勃發展。人口老化和生活方式的改變,例如長時間站立或久坐,導致靜脈曲張及相關疾病的發生率上升。此外,人們對潛在風險的健康意識不斷增強,意識到應在潰瘍和深層靜脈栓塞症( DVT)等併發症發生前進行治療,這促使人們尋求醫療干預。治療技術也不斷發展,雷射手術、射頻消融和硬化療法等更先進的治療方法相繼問世,為大眾提供了更有效率、更微創的治療方法。因此,門診手術的日益普及推動了對微創治療的需求。
美國正崛起為靜脈曲張治療的主要區域市場。美國市場的成長動力主要來自消費者日益增強的健康意識以及相關醫療技術的進步。此外,老年人口的成長以及久坐不動的生活方式導致靜脈曲張患者人數的增加,從而推高了靜脈曲張治療市場對優質產品的需求。同時,大眾對未經治療的靜脈曲張所帶來的健康危害(例如慢性疼痛和靜脈潰瘍)的認知不斷提高,也促使大眾積極參與治療。包括雷射療法、射頻消融術和硬化療法在內的微創治療技術的創新,使治療更加安全、快速和便捷,進一步加速了市場成長。
治療技術的進步
靜脈雷射治療(EVLT)、射頻消融術(RFA)和超音波引導硬化療法的持續進步,正推動治療方法從侵入性手術轉向微創(MI)和非手術治療。對於患者而言,這些新技術有望帶來更快的康復、更輕的疼痛和更低的術後併發症風險,導致手術越來越受歡迎。 2023年,全球微創手術市場價值529億美元。根據IMARC Group的報告,預計到2032年,該市場規模將達到910億美元,2024年至2032年的複合年成長率(CAGR)為6%。雷射和射頻設備的進一步發展,結合影像技術,能夠更精準地治療受累靜脈,這推動了靜脈曲張治療的需求。各公司正將收入集中投入研發,以最大限度地利用現有技術並創造新的創新。
醫學界的變革
透過國際合作,醫療專業人士正在交流最佳實踐和技術,以提高全球醫療品質。例如,在2023年6月獲得FDA核准後,VVT Medical宣布與Methapharm達成策略性分銷協議,在美國銷售其ScleroSafe平台。此次合作旨在利用Methapharm在靜脈曲張治療方面的專業知識,並透過ScleroSafe創新的非熱能、非腫脹技術革新治療方式。此類全球交流透過規範醫療品質和使先進治療技術惠及不同地區,促進了靜脈曲張治療市場的成長。醫療旅遊也是一個重要因素,越來越多的患者出國尋求更經濟實惠、高品質的治療。 2023年,全球醫療旅遊業的產值達到1,197億美元。根據 IMARC 集團的估計,從 2024 年到 2032 年,該市場預計將以 20.1% 的複合年成長率成長,到 2032 年達到 6508 億美元。全球化提高了全球靜脈曲張治療的可及性,治療品質也得到了提升,這反過來又促進了市場擴張和技術進步。
監管機構的核准和支持
獲得監管部門的核准對於靜脈曲張治療方案的研發至關重要。監管機構為新的醫療設備和治療方法制定了嚴格的標準和明確的核准程序。這種嚴格的監管環境激勵企業投資於研發和臨床試驗,並推動創新。治療方法獲得監管部門的核准有助於建立醫護人員和患者之間的信任和信心,確保市場上有安全有效的治療選擇。此外,健全的監管體系能夠加速尖端治療方法的市場准入和推廣,並拓寬現代靜脈曲張治療方案的選擇範圍。 2024年4月,VVT Medical的ScleroSafe™器材獲得韓國食品藥物管理局(KFDA)的核准,標誌著VVT Medical在韓國市場取得了重大里程碑式的進展。先前,ScleroSafe™已獲得美國FDA 510(k)認證和CE標誌,進一步證實了其作為靜脈曲張治療方案的可靠性。
The global varicose vein treatment market size was valued at USD 479.5 Million in 2025. Looking forward, IMARC Group estimates the market to reach USD 710.8 Million by 2034, exhibiting a CAGR of 4.34% from 2026-2034. North America currently dominates the market, holding a market share of over 47.8% in 2025. The growing elderly population, technological advancements in minimally invasive (MI) procedures, increasing awareness and healthcare spending, and key players focusing on innovation and strategic collaborations to expand treatment options and geographic reach are some of the factors impelling the market growth.
The market is gaining impetus due to the introduction of new, effective, and minimally invasive varicose vein treatment options. The rising geriatric population and lifestyle changes, such as prolonged standing or sedentary activities, are pushing the incidence of varicose veins and resulting diseases. Besides, health awareness concerning potential risks treated before reaching complications such as ulcers or deep vein thrombosis is convincing people to take medical intervention. Moreover, treatment technologies have migrated to more advanced procedures, such as laser surgery, radio frequency ablation, and sclerotherapy, creating more streamlined and less invasive interventions that are also within reach of the average person. As such, outpatient procedures have made a greater demand for minimally invasive treatments.
The United States has emerged as a key regional market for varicose veins treatment. The market in the US is propelled as consumers are becoming more aware about their healthcare needs, and similar medical developmental changes. Moreover, aging populations with sedentary lifestyles create rising numbers of people with varicose veins, thus generating increasing demand in the VVT market for better products. Moreover, the high public awareness levels on adverse health impacts of untreated varicose veins such as chronic pain and venous ulcers have posed as motivating factors for public intervention. Technological innovations, including minimally invasive procedures like laser therapy, radiofrequency ablation, and sclerotherapy, are making treatments safer, faster, and more accessible, further driving market growth.
Technological advancements in treatment
Ongoing advancements like endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and ultrasound-guided sclerotherapy are changing treatment approaches from invasive surgeries to minimally invasive (MI) and non-surgical options. For patients, such new technologies promise quicker recovery, less pain, and smaller chances of post-operation complications, which is causing the popularity of the surgeries to grow. In 2023, the size of the global minimally invasive surgery market was USD 52.9 Billion. As per the report by the IMARC Group, the market is expected to reach USD 91.0 Billion by 2032, exhibiting a CAGR of 6% during 2024-2032. Further development of lasers and radiofrequency devices in combination with imaging technologies for more pinpoint treatment in the ailing veins is driving the varicose vein treatment demand. Companies are channelizing their revenues for research and development (R&D) to make the best use of technologies existing and to come up with new innovations.
Globalization of healthcare
By partnering internationally, healthcare professionals exchange best practices and technologies, enhancing the quality of treatment globally. For instance, VVT Medical announced a strategic distribution agreement with Methapharm to market its ScleroSafe platform in the USA, following FDA approval in June 2023. This collaboration leverages Methapharm's expertise in varicose veins, aiming to transform treatment with ScleroSafe's innovative, non-thermal, non-tumescent technique. This worldwide exchange guarantees that advanced treatment techniques are available in different areas with standardization of care quality, supporting the varicose vein treatment market growth. Medical tourism is also a factor, with patients traveling overseas in search of top-notch treatments at more affordable prices. In 2023, the medical tourism industry in the world was valued at USD 119.7 billion. The IMARC Group estimates the market would expand at a CAGR of 20.1% from 2024 to 2032, reaching USD 650.8 billion in 2032. Globalization leads to increased accessibility and improved quality of varicose vein treatments worldwide, supporting market expansion and technological progress.
Regulatory approvals and support
Obtaining regulatory approvals is essential for the development of varicose vein treatment. Regulatory agencies establish stringent criteria and provide clear approval procedures for new medical devices and treatments. The strict regulatory landscape motivates companies to invest in research and clinical trials to drive innovation. The approval of treatments by authorities builds trust and confidence between healthcare providers and patients, guaranteeing the presence of secure and efficient choices in the market. Furthermore, robust regulations can accelerate the entry of cutting-edge treatments into the market, quickening their adoption and expanding the range of modern options for varicose vein treatment. In April 2024, VVT Medical achieved a major milestone in the Korean market with the approval of its ScleroSafe(TM) device by the Korean Ministry of Food and Drug Safety. This was after the FDA 510(k) clearance and CE Mark, confirming ScleroSafe(TM) as a dependable option for varicose vein treatment.
Ablation devices are an important segment, especially radiofrequency and laser ablation devices, as they are preferred in the treatment of varicose veins. These are effective in shutting off problematic veins with ways that are less invasive than those used hitherto, thereby inflicting less pain and delivering the patient to recovery quickly. Radiofrequency ablation devices utilize thermal energy to heat and collapse the vein, while laser ablation uses light energy to accomplish similar outcomes, providing effective options for patients who prefer less invasive treatments. In 2023, the market size of ablation devices worldwide reached USD 5.9 billion. IMARC Group forecasts that the market will reach a value of USD 14.4 billion by 2032, showing a 10.2% CAGR from 2024 to 2032.
Sclerotherapy injections have a solid presence in the industry, thereby influencing the varicose vein treatment market revenue. This technique includes injecting a solution into the varicose veins, which results in scarring and redirecting blood to healthier veins, ultimately causing the treated vein to vanish. The technique is used because of its effectiveness in addressing minor varicose veins and spider veins, its ease of use, and its reasonable cost. It is particularly popular in outpatient settings, where fast recovery is an important factor.
Others encompass a range of additional options, such as compression stockings and surgical procedures. Surgical procedures, while less frequently used now due to the increase in minimally invasive (MI) techniques, are still utilized in serious situations when other treatments do not work. This part serves a wide range of patients, providing options from basic preventive care to extensive surgical treatments.
Injection sclerotherapy leads the market with around 70% of varicose vein treatment market share in 2025. Injection sclerotherapy leads the market due to its effectiveness, low level of invasiveness, and cost-effectiveness. The process includes injecting a sclerosant solution into the varicose veins to irritate the vein walls, leading them to collapse and bond. As time passes, the vein that has been treated fades away as it gets absorbed back into the surrounding tissue. The popularity of sclerotherapy is enhanced by its ability to be performed in outpatient settings, its quick resolution of cosmetic concerns and discomfort from small varicose and spider veins, and its short recovery time, making it a preferred option for patients wanting both effectiveness and convenience. In 2023, the sclerotherapy market in the world was valued at US$ 1.2 billion. The IMARC Group projects that the market will expand at a compound annual growth rate (CAGR) of 5.5% from 2024 to 2032, when it reaches US$ 2.0 billion in 2032.
Hospitals leads the market with around 38.2% of market share in 2025. Hospitals dominate the market due to their extensive treatment options and ability to manage complicated cases that require advanced medical interventions, shaping a positive varicose vein treatment market outlook. They have the required infrastructure to offer various types of treatments for varicose veins, including less invasive procedures like sclerotherapy and endovenous ablation and more aggressive techniques such as surgical ligation and stripping. This benefits a strong confidence from patients who are looking for dependable and efficient treatments from specialized vascular surgeons and interventional radiologists. Moreover, hospitals play a key role in are frequently the top choice for patients with advanced varicose veins who may need comprehensive care from various healthcare providers and extended monitoring, solidifying their position in the market.
Regional Analysis
In 2025, North America accounted for the largest market share of over 47.8%. North America holds biggest share in the market, mainly due to substantial healthcare expenditure, cutting-edge medical technologies, and a solid healthcare system. This area, encompassing both the United States and Canada, shows a high need for minimally invasive (MI) procedures because of a high number of varicose veins in its elderly residents. As per the 2023 US Census Bureau report, the number of people in the US aged 65 and above was projected to increase by 47% from 58 million in 2022 to 82 million by 2050. Furthermore, it is expected that the percentage of people in this age range in the overall population will rise from 17% to 23%. Furthermore, North America is advantaged by having top healthcare firms and a strong regulatory framework that encourages quick uptake of new technologies. The strong presence of the region in the global market is also influenced by its extensive insurance coverage and high level of patient consciousness.
UNITED STATES VARICOSE VEIN TREATMENT MARKET ANALYSIS
In 2025, the United States accounts for 95.00% of the varicose vein treatment market in North America. It is growing in a steady line due to enhanced awareness and resultant demand for a non-invasive procedure. Journal of Vascular Surgery: Venous and Lymphatic Disorders reported that in the United States, about 24% adults have visible varicose veins, and this figure is estimated for about 6% with visible evidence of advanced chronic venous disease. With increasing modern treatment methods, including endovenous laser therapy and radiofrequency ablation, the market is greatly benefited. These minimally invasive procedures are becoming popular because they have proven to be more effective, require less recovery time, and involve fewer complications, so the demand for them is growing constantly. Market leaders include Medtronic, Boston Scientific, and CooperSurgical. Public and private healthcare sectors both contribute to the growth of this market. Government initiatives in health and wellness further support the growth of the market, and technological advancements such as robotic-assisted procedures enhance the quality of care and provide opportunities for the market.
EUROPE VARICOSE VEIN TREATMENT MARKET ANALYSIS
Varicose vein treatment in Europe is growing as a result of the aging population and growing concern with health and wellness. According to Europe PMC, varicose veins are a very common condition in Europe and appear in 35% of adult whites. Such contributions from leading countries like Germany and the UK follow healthcare system investments and the increase of demand for minimally invasive procedures. New treatments such as laser therapy and sclerotherapy are becoming popular due to the high success rates with low risks of complications. Market leaders include Medtronic and Varian Medical Systems, with public-private partnerships contributing to the further advancement of treatment methods. Non-invasive treatments are likely to be the norm for the region with a focus on the alleviation of the pressure on healthcare services.
ASIA PACIFIC VARICOSE VEIN TREATMENT MARKET ANALYSIS
The market in Asia Pacific is growing fast due to robust healthcare infrastructure and awareness about vascular diseases. According to an industry report, in India, prevalence of varicose veins is between 5% and 30%. A national survey showed the prevalence of varicose vein is 8.9% of the population in China, or over 100 million people. Healthcare in China 2023. The rising disposable income and aesthetic treatment needs are also promoting the varicose vein treatment market. Invasive treatments like sclerotherapy and laser surgery are gaining ground because they have a lower cost and less time for recovery. Philips and Alcon are now upgrading their offerings. There has been a high level of engagement with training and development programs between local governments and these companies, to improve health outcomes.
LATIN AMERICA VARICOSE VEIN TREATMENT MARKET ANALYSIS
Market for varicose vein treatment is growing in Latin America, as increasing healthcare access and rising incomes boost demand for aesthetic procedures. A study of 1,755 adults in a rural town in Brazil revealed 47.6% of people with varicose veins. Of these, 37.9% of men and 50.9% of non-pregnant women were affected. The prevalence of moderate to severe varicose veins was 21.2%. Healthcare expenditure in Brazil totalled USD 23 Billion in 2023, as per industry reports. The government is investing in accessibility to specialized treatments. About 5 million Latin Americans undergo varicose vein treatments every year, with the majority of treatments happening in Brazil and Mexico. Local manufacturers are increasingly producing advanced treatment devices, further supporting varicose vein treatment market growth. There is a cooperation between private and public healthcare systems in increasing the availability of modern treatment options. It drives innovation and improves patient outcomes.
MIDDLE EAST AND AFRICA VARICOSE VEIN TREATMENT MARKET ANALYSIS
The varicose vein treatment market in the Middle East and Africa is growing steadily, driven by the increasing accessibility of healthcare services and patient awareness. According to industrial reports, the prevalence of varicose veins in the Middle East varies according to location and population, with studies reporting varying prevalence rates. In Saudi Arabia, it has been established that 62% of the population has VVs, and their annual incidence has increased by approximately 5% for females and 2% for males. In Cairo, Egypt, over 51% of the population suffers from VVs, while in Western Jerusalem, a survey showed that 29% of females and 10% of males in a heterogeneous population suffered from VVs. In Saudi Arabia, healthcare expenditure for 2023 is estimated at USD 16.5 billion, which has been expanding the specialized treatment facilities. International collaboration and health tourism are further demanding varicose vein treatments in the region since patients are trying to find a more affordable solution abroad.
Key players in the market are working diligently on research and development (R&D) to improve the efficiency and safety of current treatments, as well as pursuing approval for new solutions. Leading varicose vein treatment companies are concentrating on broadening their range of products by forming strategic partnerships, merging, and acquiring other companies to strengthen their global market position. For example, DXI Capital Corp. revealed on November 24, 2023, its plan to acquire the entirety of V.V.T. Med Ltd. and Exiteam Acquisition Corp. through a non-binding letter of intent. This move was made to help DXI fulfill TSX Venture Exchange's listing criteria and sustain VVT's varicose vein treatment operations. Furthermore, there is a strong focus on marketing and educational initiatives to increase awareness about the progress in varicose vein treatments among both healthcare providers and patients. These initiatives focus on promoting the use of modern and less intrusive therapies, expanding the range of treatment choices in the market.